Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | CBLB | Q13191 | 7/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926221 | 0.83 | GRN (0.55) | PSMB5 | |
| SCHEMBL607813 | 0.82 | ADAM17 (0.47) | ELANEHDAC3HDAC1HDAC2 | |
| SCHEMBL2934925 | 0.82 | KDM4E (0.47) | ELANECTSGCYP3A4PSMB1CMA1 | |
| SCHEMBL2931761 | 0.82 | CTSA (0.47) | ELANECTSGCYP3A4PSMB1CMA1 | |
| SCHEMBL2934898 | 0.82 | CTSA (0.47) | EGLN1ELANECTSGCYP3A4PSMB1 | |
| SCHEMBL2926118 | 0.81 | CCR1 (0.47) | ELANECTSGCYP3A4PSMB1CMA1 | |
| SCHEMBL2925992 | 0.81 | HDAC3 (0.42) | EGLN1ELANECTSGCYP3A4PSMB1 | |
| SCHEMBL2933374 | 0.81 | PSMB5 (0.48) | ELANECTSGCYP3A4PSMB1CMA1 | |
| SCHEMBL2930873 | 0.81 | CCR1 (0.53) | CYP3A4 | |
| SCHEMBL2927875 | 0.80 | ELANE (0.47) | ELANECTSGCYP3A4PSMB1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | claimed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | claimed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | claimed |
| US-20140121182-A1 | PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE | CEPHALON, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8541590-B2 | Proteasome inhibitors and processes for their preparation, purification and use | CEPHALON, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120270840-A1 | Proteasome inhibitors and processes for their preparation, purification and use | CEPHALON INC. (US) | 2012-10-25 | — | — | US | disclosed |
| EP-1846424-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270840-A1 | Proteasome inhibitors and processes for their preparation, purification and use | PSMB1, PSMB11, PSMB7 | EGLN1 2386/4885ELANE 3573/4885CTSG 1535/4885 |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | EGLN1 1326/4885ELANE 1737/4885CTSG 779/4885 |
| US-20140121182-A1 | PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE | PSMB1, PSMB11, PSMB7 | EGLN1 1741/4885ELANE 3714/4885CTSG 2165/4885 |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | EGLN1 1326/4885ELANE 1737/4885CTSG 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.